Some comments in here talk about Active Pharmaceutical Ingredient or excipients, but a generic isn't given approval based on their active ingredients. This is one of the common objection given to the patent model for drugs, in that generics still need to show that their version with their unique combination of active and excipients have the same therapeutic effect, which normally means that they need to conduct new studies. The only way you can "copy" a drug is if you make a identical copy in every aspect, including the excipients, and the patent don't include enough information to do that.
If the therapeutically value of an excipient is that they change the absorption rate of the active ingredient, then that effects the bioequivalence of the drug. For example, comments in this thread refereed to different sized particles in inhalers which can have a direct effect on absorption rates.
If we disregard the therapeutic effect from the rate and extent that the "active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives" reaches the site of drug action, what is left to change the therapeutic effect?
One of my former colleagues once made a "drug" where the excipient actually was therapeutically valuable while the listed API was barely better than placebo. Luckily we didn't submit it for approval.
That seems... ridiculously illegal.
I believe there are some topical OTC drugs that work this way :-(
Or did you think making unlicensed drugs is illegal? Of course it isn't -- that's what drug development IS. It's not legal to give such a drug to humans without a valid IND that hasn't been rejected by the FDA but formulating, doing in vitro testing and animal in vivo testing is all perfectly legit.
https://www.nytimes.com/2015/06/17/business/generic-ritalin-...
The article do bring up a major issue when the FDA changed their decision in regard to a generic. The market and even the FDA itself is having a problem to address the problem. The doctor is quoted: “If the F.D.A. rules it’s not the same, how can it be sold? I don’t understand the rationale for that happening.”. It is indeed odd and a major complaint about how the FDA managed this case.
This is a strictly regulated industry in Europe and I don't see them getting-away-with-it if there were health issues for the patient. I'm surprised to see so many comments here agreeing with the notion that generics are of lesser effect.
[1] prescription drugs, not over the counter paracetamol.
I'm not saying they are exactly equivalent -- things like particle sizes, buffers, release speed, etc (which are often different in different formulations) are known to make a difference.
It is, however, extremely unlikely (to the point of impossibility) that every single brand name is better than every single equivalent generic. I have anecdotal evidence about a specific generic working significantly better than a related name brand for a specific person.
There are specific studies showing a specific brand name is better than a specific [set of] generics. In the few cases I looked into it, that study was financed by the brand. They wouldn't publish a result saying the generic is better if that was the conclusion (and it's usually possible to p-hack a favorable result). I am not aware of generic manufacturers commissioning a study either way.
I can accept a "75% of brands are better than generic" if it came from a well defined study. It's statistically impossible that "100% of brands are equal or better to generics".
So homoeopathic remedies could be a useful thing for doctors to prescribe to people who think they need a prescription but don't actually need one (certainly much better than antibiotics, which I'm pretty sure have sometimes filled this niche in the past).